TR200002145T2 - İnsan IL-12'ye karşı antikorlar - Google Patents

İnsan IL-12'ye karşı antikorlar

Info

Publication number
TR200002145T2
TR200002145T2 TR2000/02145T TR200002145T TR200002145T2 TR 200002145 T2 TR200002145 T2 TR 200002145T2 TR 2000/02145 T TR2000/02145 T TR 2000/02145T TR 200002145 T TR200002145 T TR 200002145T TR 200002145 T2 TR200002145 T2 TR 200002145T2
Authority
TR
Turkey
Prior art keywords
human
antibodies
heterodimer
specific
bioactivity
Prior art date
Application number
TR2000/02145T
Other languages
English (en)
Turkish (tr)
Inventor
Kent Gately Maurcie
Howard Presky David
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22106938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200002145(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200002145T2 publication Critical patent/TR200002145T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TR2000/02145T 1998-01-23 1999-01-15 İnsan IL-12'ye karşı antikorlar TR200002145T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7233398P 1998-01-23 1998-01-23

Publications (1)

Publication Number Publication Date
TR200002145T2 true TR200002145T2 (tr) 2000-11-21

Family

ID=22106938

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02145T TR200002145T2 (tr) 1998-01-23 1999-01-15 İnsan IL-12'ye karşı antikorlar

Country Status (18)

Country Link
US (1) US6225117B1 (enExample)
EP (2) EP1818343B1 (enExample)
JP (3) JP4481489B2 (enExample)
KR (1) KR100764256B1 (enExample)
CN (2) CN100374466C (enExample)
AR (2) AR014459A1 (enExample)
AT (2) ATE357459T1 (enExample)
AU (1) AU759624B2 (enExample)
BR (1) BR9907743A (enExample)
CA (1) CA2318052C (enExample)
CY (2) CY1106594T1 (enExample)
DE (1) DE69935574T2 (enExample)
DK (2) DK1818343T3 (enExample)
ES (2) ES2284242T3 (enExample)
PT (2) PT1818343E (enExample)
TR (1) TR200002145T2 (enExample)
WO (1) WO1999037682A2 (enExample)
ZA (1) ZA99452B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399379B1 (en) 1992-09-29 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p35 subunit expression
US20060084061A1 (en) * 2002-06-11 2006-04-20 Marcusson Eric G Methods for blocking adipocyte differentiation and triglyceride accumulation with interleukin 12 p35 inhibitors
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6448081B1 (en) 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
JP3579355B2 (ja) 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
CA2399387C (en) * 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
US8080247B2 (en) 2000-08-07 2011-12-20 Janssen Biotech, Inc. Anti-IL-12 antibodies
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
PT1585546E (pt) * 2002-12-30 2008-11-14 Biogen Idec Inc Antagonistas de kim-1 e sua utilização para modular o sistema imunitário
CA2550155C (en) * 2003-12-15 2015-03-17 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
UA96922C2 (en) * 2005-06-30 2011-12-26 Эббот Леборейториз Il-12/p40 binding protein
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
EP2527364A1 (en) 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
NZ602511A (en) 2008-03-18 2014-03-28 Abbvie Inc Methods for treating psoriasis
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
FI13575Y1 (fi) 2018-09-24 2024-03-26 Janssen Biotech Inc IL12/IL23-vasta-aine käytettäväksi turvallisessa ja tehokaassa menetelmässä haavaisen paksusuolitulehduksen hoitamiseksi
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5809360A (en) * 1996-08-07 1998-09-15 Agfa Division - Bayer Corporation Cassette for storing and accessing plates within an automated plate handler
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies

Also Published As

Publication number Publication date
CN101274962A (zh) 2008-10-01
CA2318052C (en) 2012-07-03
JP2009197008A (ja) 2009-09-03
CN100374466C (zh) 2008-03-12
ES2284242T3 (es) 2007-11-01
ATE553129T1 (de) 2012-04-15
EP1049717B1 (en) 2007-03-21
CA2318052A1 (en) 1999-07-29
WO1999037682A2 (en) 1999-07-29
JP2002501085A (ja) 2002-01-15
BR9907743A (pt) 2000-10-17
EP1818343B1 (en) 2012-04-11
DE69935574T2 (de) 2007-12-06
DK1818343T3 (da) 2012-07-16
AU759624B2 (en) 2003-04-17
ES2386262T3 (es) 2012-08-14
ZA99452B (en) 1999-07-23
CY1112927T1 (el) 2016-04-13
DE69935574D1 (de) 2007-05-03
CY1106594T1 (el) 2012-01-25
PT1818343E (pt) 2012-07-12
EP1818343A2 (en) 2007-08-15
US6225117B1 (en) 2001-05-01
CN1288468A (zh) 2001-03-21
EP1818343A3 (en) 2007-08-22
KR20010034315A (ko) 2001-04-25
JP4481489B2 (ja) 2010-06-16
AR061801A2 (es) 2008-09-24
WO1999037682A3 (en) 1999-11-18
AR014459A1 (es) 2001-02-28
PT1049717E (pt) 2007-05-31
ATE357459T1 (de) 2007-04-15
KR100764256B1 (ko) 2007-10-05
AU2517799A (en) 1999-08-09
JP2013139458A (ja) 2013-07-18
EP1049717A2 (en) 2000-11-08
DK1049717T3 (da) 2007-07-30

Similar Documents

Publication Publication Date Title
TR200002145T2 (tr) İnsan IL-12'ye karşı antikorlar
HRP20180941T1 (hr) Protutijela protiv il-17
ATE469176T1 (de) Modifizierter anti-tnf antikörper
EA200300663A1 (ru) Антагонисты cxcr3
GEP20105118B (en) Anti-vegf antibodies
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
DK1102596T3 (da) Peptidantagonister af zonulin og fremgangsmåder til anvendelse heraf
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
NZ547157A (en) Interferon Alpha Antibodies and their uses
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
EA200501505A1 (ru) Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях
MX9704897A (es) Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano.
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
DK1190056T3 (da) Human cytokin receptor
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
ITRM20020049A0 (it) Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
DK1430133T3 (da) En oplöselig Toll-lignende receptor
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
DE69427484D1 (de) Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma
BRPI0508082A8 (pt) Anticorpo monoclonal de tenascina antihumano